[The treatment of chronic myeloleukemia with recombinant alfa-2 interferon].

A trial has been conducted of recombinant alpha 2-interferon (reaferon) used in 32 patients with Ph'[correction of Rh']-positive chronic myeloid leukemia (CML). A chronic stage was in 3, transient in 3 and blast in 1 patients. 25 CML patients were newly diagnosed.

[A method for predicting the course of chronic myeloleukemia].

The effects of a synthetic prostaglandin E1 (PGE1) analog on colony-forming activity in agar cultures of peripheral blood and bone marrow was studied in 28 patients with chronic myeloid leukemia and 9 hematologically healthy subjects. Addition of PGE1 to normal bone marrow culture was followed by a significant drop in the number of colonies per dish in 8 out of the 9 subjects. In leukemic patients, the effect was bizarre.

[An unusual case of a basophilic variant of chronic myelogenous leukemia].

The described basophilic variant of CML in blastic crisis was characterized by a distinct hyperhistaminemia, a moderate hypocoagulation and an insufficiently effective cytostatic therapy. Cell kinetic was characterized by a marked diminution of the whole marketing index (with H3-thymidine) of blasts and immature basophils with simultaneous prolongation of the generation time in comparison to myeloblasts at the chronic stage of the CML. Aneuploid cell clones prevailed in the bone-marrow.

[Characteristics of clonal evolution in patients with myelocytic leukemia].

The authors report the results of the clinical, cytochemical, cytogenetic and kinetic studies (3H-thymidine autoradiography and scanning integrating cytospectrophotometry of DNA) in a male patient with chronic myeloleukemia with blast infiltration of the lymph nodes. Analysis of the karyotype and kinetic aspects of leukemic cells obtained from the blood, bone marrow, spleen and hyperplastic lymph nodes was performed over time at different disease periods. Based on the data obtained the authors suggest that aneuploid blasts may maturate before segmented granulocytes.